Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Société des Produits Nestlé (SPN)
Age
1–4
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Provision of signed and dated informed consent from subject and/or subject's parents or legally authorized representatives (LAR).
Male or female, 12 to 48 months of age, inclusive.
Subjects requiring enteral feeding for \> 7 days (in hospital, long-term care facility or at home).
Subjects receiving enteral tube-feeding (nasogastric feeding tube or percutaneous endoscopic gastrostomy \[PEG\] tube) to provide 90% or more of their nutritional needs at the time of study entry.
Subject is clinically stable (i.e. absence of any significant gastrointestinal symptoms during the past 7 days), in the opinion of the investigator.
You may not be if
Subjects receiving partial or total parenteral nutrition (e.g. for short bowel syndrome and other causes of intestinal failure).
Subjects with ongoing or intermittent significant gastrointestinal symptoms during the 7 days before enrollment.
Oncology patients recovering from chemotherapy or radiotherapy for hematological malignancies or solid tumors (last treatment within 3 months of enrollment).
Congenital immunodeficiency syndromes (SCID etc).
Cystic fibrosis and other causes of fat malabsorption (lymphatic malformations/lymphangiectasis).
Subjects with any clinically significant condition (e.g. severe malnutrition, congenital heart disease, etc) that, in the investigator's opinion, would preclude inclusion in the study.
Subjects at risk for poor compliance to the study protocol in the investigator's opinion.
Currently participating in another conflicting trial or participated in an investigational trial within 30 days of enrollment.
Known hypersensitivity to PHGG or to any other ingredients in the investigational product.
Clareo Health | Study to Evaluate the Tolerance and Safety of a Peptide-based Enteral Formula with Partially Hydrolyzed Guar Gum (PHGG)
